Increased procoagulant activity of red blood cells in the presence of cisplatin

Chinese Medical Journal

Volumn 121, Issue 18, 2008, Pages 1775-1780

  Lü, Cheng Fang ^a   Yu, Hong Juan ^a   Hou, Jin Xiao ^a   Zhou, Jin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; Lactadherin; Phosphatidylserine; Procoagulant activity; Red blood cell

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CISPLATIN; LACTADHERIN; PHOSPHATIDYLSERINE; THROMBIN;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BREAST CANCER; CELL ACTIVITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE COUNT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL;

EID: 54349114519     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200809020-00004     Document Type: Article

References (38)

1. Boas FE, Forman L, Beutler E. Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia. Proc Natl Acad Sci U S A 1998; 95: 3077-3081.
2. Ho CH. The hemostatic effect of adequate red cell transfusion in patients with anemia and thrombocytopenia. Transfusion 1996; 36: 290.
3. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood 2001; 98: 3228-3233.
4. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, et al. Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007; 27: 414-421.
5. Shin JH, Lim KM, Noh JY, Bae ON, Chung SM, Lee MY, et al. Lead induced procoagulant activation of erythrocytes through phosphatidylserine exposure may lead to thrombotic diseases. Chem Res Toxicol 2007; 20: 38-43.
6. Luzzato G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990; 17: 147-158.
7. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997; 78: 133-136.
8. Lee AYY, Levine MN. The thrombophilic state induced by therapeutic agents in cancer patients. Semin Thromb Haemost 1999; 25: 137-145.
9. Freytes CO. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Haemost 2007; 33: 389-396.
10. Gallus AS. Prevention of post operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 1997; 78: 126-132.
11. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N Engl J Med 1989; 320: 479-484.
12. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996; 14: 2731-2737.
13. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant chemotherapy for breast cancer. J Clin Oncol 1991; 9: 286-294.
14. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five drug chemotherapy regimen. A study of 159 patients. Cancer 1984; 54: 1264-1268.
15. Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994; 12: 1266-1271.
16. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-407.
17. Donati MB, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol 2001; 106: 18-24.
18. Hvarregaard J, Andersen ME, Berglund L, Rasmussen JT, Petersen TE. Characterization of glycoprotein PAS 6/7 from membranes of bovine milk fat globules. Eur J Biochem 1996; 240: 628-636.
19. Le Gac S, Vermes I, van den Berg A. Quantum dots based probes conjugated to annexin V for photostable apoptosis detection and imaging. Nano Lett 2006; 6: 1863-1869.
20. Gilbert GE, Arena AA. Activation of the factor VIIIa factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl L serine. J Biol Chem 1996; 271: 11120-11125.
21. Govers Riemslag JW, Janssen MP, Zwaal RF, Rosing J. Prothrombin activation on dioleoylphosphatidylcholine membranes. Eur J Biochem 1994; 220: 131-138.
22. Brunauer LS, Moxness MS, Huestis WH. Hydrogen peroxide oxidation induces the transfer of phospholipids from the membrane into the cytosol of human erythrocytes. Biochemistry 1994; 33: 4527-4532.
23. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86: 66-74.
24. Stubbs J, Lekutis C, Singer K, Bui A, Yuzuki D, Srinivasan U, et al. cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidemal growth factor like domains linked to factor VIII like sequences. Proc Natl Acad Sci U S A 1990; 87: 8417-8421.
25. Shi J, Gilbert GE. Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid binding sites. Blood 2003; 101: 2628-2636.
26. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002; 4: 465-473.
27. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002; 3: 27-34.
28. Anders JC, Grigsby PW, Singh AK. Cisplatin chemotherapy (without erythropoietin) and risk of life threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature. Radiat Oncol 2006; 1: 14.
29. Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005; 103: 994-999.
30. Jacobson G, Kamath R, Smith B, Goodheart M. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol 2005; 96: 470-474.
31. Helley D, Eldor A, Ginot R, Ducrocq R, Guillin MC, Bezeaud A. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassaemia. Thromb Haemost 1996; 76: 322-327.
32. Yamaja Setty BN, Koneti Rao A, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood 2001; 98: 3228-3233.
33. Walsh J, Wheeler H, Geczy C. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 1992; 81: 480-488.
34. Togna G, Togna A, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res 2000; 99: 503-509.
35. Cool R, Herringon J, Wong L. Recurrent peripheral. arterial thrombosis induced by cisplatin and etoposide. Pharmacotherapy 2002; 22: 1200-1204.
36. Licciarello J, Moake J, Rudi C, Karp D, Hong W. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin based chemotherapy. Oncology 1985; 42: 296-300.
37. Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate. and 5-fluorouracil. Cancer 1989; 63: 1303-1307.
38. Berg CP, Engels IH, Rothbart A, Lauber K, Renz A, Schlosser SF, et al. Human mature red blood cells express caspase 3 and caspase 8, but are devoid of mitochondrial regulators of apoptosis. Cell Death Differ 2001; 8: 1197-1206.